ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Mechanism of Buzhong Yiqi decoction for Hashimoto's thyroiditis: insights from gut microbiota and metabolomics.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the effect of Buzhong Yiqi decoction (BZYQ) and its potential mechanism by conducting a comprehensive analysis of intestinal microbiota and metabolomics in autoimmune thyroiditis (AIT) rats.
methodsAn AIT model with antibiotic cocktail were established. After 8 weeks of intervention with BZYQ, the levels of anti-thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TGAb) were measured. Pathological changes were assessed using hematoxylin and eosin staining. Changes of gut microbiota and fecal metabolites were analyzed through 16S RNA sequencing and metabolomics analysis.
resultsBZYQ intervention improved pathological damage of thyroid gland in AIT rats and significantly reduced the levels of anti-thyroid antibodies. Additionally, it had an ameliorative effect on the pathological damage of the colon. Also, BZYQ increased the abundance of Lactobacillus reuteri, reversing the dysbiosis of the gut microbiota. And BZYQ could regulate tryptophan metabolism of tryptophan to reverse metabolic disorders in HT. The correlation analysis indicated a close relationship between tryptophan metabolism and Lactobacillus reuteri.
conclusionsBZYQ is a promising therapeutic approach for HT. Its mechanism in treating HT may be associated with the regulation of gut microbiota dysbiosis and the improvement of gut-derived metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.